BioMarin Pharma (BMRN) Misses Q2 EPS by 5c, Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $108 at BMO Capital
August 5, 2020 9:46 AM EDTBMO Capital analyst George Farmer raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $108.00 (from $94.00) while maintaining a Market Perform rating.
The analyst commented, "Following model adjustments, we increase our PT to $108 from $94 and maintain our Market Perform rating ahead... More
